Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis
1 other identifier
observational
80
1 country
2
Brief Summary
Juvenile Idiopathic Arthritis (JIA), the most common rheumatologic chronic disease in children, is defined as arthritis persisting for at least 6 weeks with no known cause in a patient under the age of 16. The term JIA is an umbrella that includes very different diseases. The current International League of Associations for Rheumatology (ILAR) classification divides JIA patients into 7 categories based on number of involved joints and time of involvement, presence of systemic symptoms, psoriatic findings and spondyloarthritis. This classification groups together patients with different disease and divides patients with the same disease. In the first case, unifying distinct diseases could lead to undifferentiated therapeutic choices, moving away from the modern concept of therapeutic personalization. In the second case, similarities between paediatric and adult arthritis could not be found. This involves both a loss of collaboration with the adult rheumatologist and the difficulty in accessing possibly effective therapies approved only for adult arthritis. In clinical practice, it is increasingly evident that the number of affected joints and the speed of joint involvement are not useful criteria for defining the type and severity of disease. Joint counts lead to underestimate the importance of joint distribution in the identification of distinct forms of arthritis. A recent study found that patterns of joint involvement represent prognostic features, so grouping patients by joint pattern and degree of localization may help clinicians tailor treatments based on predicted disease trajectories. Another important point to differentiate some forms of arthritis is the presence of enthesitis and tenosynovitis. Sometimes tendon inflammation can be not clinically evident, so ultrasound evaluation is useful to detect it. Musculoskeletal ultrasound (MSUS) has been used worldwide by adult rheumatologist, but it is beginning a useful tool also in patients with JIA. Recent studies underline the important role of MSUS findings to assess disease activity and assist disease classification. In recent years, the need has emerged to replace the ILAR criteria with a new nomenclature based on the disease biology. This approach could help clinicians to choose a personalized therapeutic strategy for patients with arthritis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2022
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 10, 2022
CompletedFirst Submitted
Initial submission to the registry
March 28, 2023
CompletedFirst Posted
Study publicly available on registry
August 23, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 15, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 15, 2026
CompletedJune 14, 2024
June 1, 2024
2.7 years
March 28, 2023
June 13, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
To evaluate disease activity by the Juvenile Arthritis Disease score during the transition to adult care
The Juvenile Arthritis Disease score (JADAS) includes 4 measures: physician's global assessment of disease activity, measured on a 0-10 visual analog scale (VAS) (0=no activity-10=maximum activity); parent global assessment of well-being, measured on a 0-10 VAS (0=very well-10=very poor); the erythrocyte sedimentation rate, normalized to a 0 to 10 scale; and a count of joints with active disease. The final score is calculated as the sum of the scores of these four components (higher scores indicate higher disease activity).
Between 14-17 years of age
To evaluate disease activity by the Health Assessment Questionnaire - Disability Index during the transition to adult care
The Health Assessment Questionnaire - Disability Index (HAQ-DI) includes 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities, with 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section the score given to that section is the worst score within the section. The 8 scores of the 8 sections are summed and divided by 8.
Between 14-17 years of age
To assess joint damage by radiological examination during the transition to adult care
Radiographs will be performed to assess the presence of joint damage
Between 14-17 years of age
Secondary Outcomes (1)
To evaluate non-inflammatory pain by the widespread pain index scale during transition to adult care
Between 14-17 years of age
Study Arms (2)
Patients at onset of juvenile arthritis
New diagnosis of JIA
Patients with juvenile arthritis in follow up
Subjects with JIA already followed at Rheumatologic Service
Eligibility Criteria
Subjects with JIA during the transition to adult care
You may qualify if:
- Subjects under the age of 18 years
- Arthritis persisting for at least 6 weeks with no known cause
You may not qualify if:
- No consent from the patients' guardians
- Patients with Systemic onset Juvenile Idiopathic Arthritis
- Patients who developed arthritis on a pre-existing inflammatory disorder such as Inflammatory Bowel Disease, and had received previous treatments
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
IRCCS Burlo Garofolo
Trieste, 34137, Italy
(Department of Medical and Biological Sciences, Rheumatology Clinic, University of Udine
Udine, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Serena Pastore, MD
IRCCS materno infantile Burlo Garofolo
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 28, 2023
First Posted
August 23, 2023
Study Start
January 10, 2022
Primary Completion
September 15, 2024
Study Completion
March 15, 2026
Last Updated
June 14, 2024
Record last verified: 2024-06